Keratinocyte IL-17RA signaling promotes neutrophil recruitment and clinical lesions in experimental epidermolysis bullosa

Avatar
Poster
Voice is AI-generated
Connected to paperThis paper is a preprint and has not been certified by peer review

Keratinocyte IL-17RA signaling promotes neutrophil recruitment and clinical lesions in experimental epidermolysis bullosa

Authors

Jukic, S.; Holscher, A.; Prinz, I.; Becher, B.; Waisman, A.; Schmidt, E.; Ludwig, R. J.; Yu, X.; Petersen, F.; Holscher, C.; Deng, F.

Abstract

Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disease (AIBD) characterized by anti-type VII collagen autoantibody-mediated tissue injury. Neutrophils have been identified as essential for dermal-epidermal separation in various in vitro and mouse models of EBA. Although interleukin-17 (IL-17) signaling promotes neutrophilic inflammation, its contribution to EBA and the relevant responding cell types remain poorly defined. We investigated the role and cellular targets of IL-17 receptor A (IL-17RA) signaling using an antibody-transfer model of EBA in mice with global IL-17RA deficiency, combined IL-17A/IL-17F deficiency, IL-17F deficiency, or myeloid cell- or keratinocyte-specific IL-17RA deletion. Complementary in vitro assays assessed IL-17A-induced chemokine expression and neutrophil migration. Global IL-17RA deficiency, combined IL-17A/IL-17F deficiency, and IL-17F deficiency significantly reduced disease severity in vivo. Keratinocyte-specific IL-17RA deletion markedly attenuated EBA, whereas myeloid cell-specific deletion did not confer protection. In vitro, IL-17A increased Cxcl1 mRNA expression in keratinocytes and fibroblasts, and conditioned media from stimulated cells promoted neutrophil migration. These findings identify keratinocytes as key cellular targets of IL-17RA signaling in experimental EBA and support a mechanism linking epithelial cytokine responses to neutrophil recruitment and tissue injury. Our data support investigating the keratinocyte IL-17RA pathway as a potential therapeutic target in EBA and related AIBD.

Follow Us on

0 comments

Add comment